Andrew J. Rae

MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.

Part of Bristol Myers Squibb Co., Ability Biomedical Corp. is a Canadian company that researches and develops chemokine-based therapeutics. The private company is based in Vancouver, Canada. Ability Biomedical was acquired by Medarex, Inc., part of Bristol Myers Squibb Co. from September 01, 2009 on August 05, 2004 for $8.43 million.

Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada.

iCo Therapeutics, Inc. is a canadian biotechnology company. It engages in the business of identification, development and commercialization of drug candidates to treat ocular and infectious diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.

Covenant House Vancouver provides shelter and services to children and youth. It offers homeless, runaway and at-risk youth between the ages of 16 and 24 with short-term residential care through its crisis program. The company was founded on September 22, 1997 and is headquartered in Vancouver, Canada.